https://scholars.lib.ntu.edu.tw/handle/123456789/610530
標題: | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | 作者: | Huang, Yen-Hsiang Hsu, Kuo-Hsuan Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh KANG-YI SU SUNG-LIANG YU Chen, Jeremy J W Chang, Gee-Chen |
關鍵字: | OPEN-LABEL; GEFITINIB; ADENOCARCINOMA; MUTATIONS | 公開日期: | 23-四月-2022 | 出版社: | SPRINGER | 來源出版物: | Targeted oncology | 摘要: | Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are the standard first-line treatment for patients with advanced and recurrent EGFR-positive non-small cell lung cancer. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/610530 | ISSN: | 1776-2596 | DOI: | 10.1007/s11523-022-00878-x |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。